Stifel maintains Buy rating on Pulmonx, $4 price target

Stifel kept a Buy rating on Pulmonx with a $4 price target, suggesting 102% upside from the last close. The company reported 6.8% YoY U.S. sales growth and 18% reduced operating expenses, with a 76.2% gross margin.

Original reporting
Published Oct 28, 2026, 4:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 4:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stifel maintains Buy rating on Pulmonx, $4 price target — source image
Decision brief

The 30-second read

Med
01

Why it matters

The rating and target could trigger short-term buying pressure.

02

Market read

Analyst coverage may move the stock higher in the near term.

03

What to watch

Potential regulatory delays or competition could temper upside.

Relevance 6/10Novelty 5/10Timing: today

Background

Stifel's analyst note highlights revenue growth, margin expansion, and cost reductions for Pulmonx.

Market effects

May lift sentiment in the pulmonary disease biotech niche.

Limited to US biotech investors.

Minor, confined to Pulmonx shareholders.

Counterpoint

Some investors may view the target as overly optimistic given limited commercial rollout.

Key entities

  • Pulmonx

    Biotech firm developing treatments for severe emphysema.

  • Stifel

    Investment bank providing the rating and price target.

Related articles

$LUNGMed

Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.